FDA seeks feedback on real-world testing for AI medical devices
The US Food and Drug Administration (FDA) is asking for public input on how to regulate AI-powered medical devices, which have rapidly expanded into clinics since ChatGPT’s 2022 release. Over 230 million people weekly now ask ChatGPT health-related questions, and AI tools now assist with drug prescriptions, X-ray interpretation, rare disease diagnosis, and administrative tasks like ordering lab…
Key points
- FDA published an August discussion paper seeking feedback on AI medical device regulation by October 19
- Over 230 million people weekly ask ChatGPT health-related questions, per OpenAI’s estimates
- Only 23% of AI health studies used real-world patient data, per *Nature Medicine* review
Current regulations vary by risk level, but AI devices often lack real-world validation. A Nature Medicine review found only 23% of AI health studies used real-world patient data, and just 19 were prospective randomized trials. Critics argue simulated tests against human physicians are insufficient, while specialized medical AI models show inconsistent accuracy gains. The FDA and global counterparts are now debating whether AI devices should follow the same rigorous standards as drugs, given their potential impact on patient care and safety.
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Policy & Regulation
All →- RFK Jr proposes linking US health data to AI for vaccine studies · 1 src
- Amazon blocks Meta’s Muse agent over credential risks and lack of identification · 1 src
- House Speaker Johnson hopes AI guardrails remain voluntary · 1 src
- Left should organize against AI obsolescence · 1 src
- US Democrat urges China-US AI treaty over superintelligence risks · 1 src
Comments
via GitHub Discussions